Select Vaccines partner ships hep E kits to hotspot
Wednesday, 08 September, 2004
Select Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
The kits, which were provided to the WHO on a humanitarian basis, will be used in the Darfur region of Sudan to help contain an outbreak of hepatitis E in the refugee camps. Select Vaccines licensed the hepatitis E rapid diagnostic kit, as well as a laboratory diagnostic to Genelabs for a 12-year term in August, in return for upfront payments and royalties.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...